Eleanor Health delivers in-person and virtual substance use disorder care using a harm-reduction, whole-person clinical model. Its care model includes medications for addiction treatment (Suboxone and Vivitrol), psychiatry, therapy, and peer recovery coaching. Eleanor operates under value-based payment structures designed to align incentives around reduced total cost of care and improved quality metrics. The company reports improved clinical outcomes and total-cost-of-care reductions across large populations. Eleanor currently has contracts with 17 payors, including five national payors, and provides care in seven states (LA, MA, NJ, NC, OH, TX, and WA). The company intends to use new capital to continue scaling its whole-person care model and expand access. Eleanor Health operates a tech-enabled, evidence-based care model for substance use disorders and mental health that combines medication-assisted therapy, psychiatry, individual and group therapy, peer recovery coaching, health navigation, and nurse case management. The company leverages proprietary technology and data-driven personalization to enable blended telehealth and in-person community care and to drive superior clinical outcomes. Eleanor reports 84% of members improving substance use, 70% improving depression and anxiety, and an 84% reduction in emergency department and inpatient utilization. It currently operates across six markets and says it will manage more than 60,000 members by the end of 2022 and be available to over 22 million people as an in-network insurance benefit. Future plans described in the articles include fostering new risk-based, population health partnerships, expanding into Texas, and continuing to build its care delivery and analytics platform to scale its model. Eleanor Health delivers outpatient addiction and mental health care through a population- and value-based medical home model that combines in-person clinics, community-based care, and a 100% virtual option. The company provides medications for substance use disorders, psychiatric evaluation, individual and group therapy, nurse care management, support for social determinants of health, and peer recovery coaching. Eleanor operates 18 clinics and a fully virtual model across Louisiana, Massachusetts, New Jersey, North Carolina, Ohio, and Washington and plans to manage more than 50,000 members under population-based partnerships by 2022. It reports strong outcomes across its footprint, including an 84% reduction in emergency department and inpatient stays, 84% improvement in substance use, 70% improvement in depression and anxiety, and NPS/eNPS scores of 72 and 71. The company intends to scale by deepening presence in existing markets, executing additional payer contracts to manage new populations, and further developing its proprietary analytics and technology platform. Eleanor recently closed a $20M Series B to support growth and meet rising payer and community demand. Eleanor Health provides value-based outpatient addiction and mental-health treatment combining medication-assisted treatment (MAT), psychiatric evaluation, medication management, individual and group therapy, peer recovery coaching, and support for social determinants of health. The model emphasizes whole-person care delivered in outpatient clinics, community settings, and at home through technology and field-based teams, with financial accountability tied to long-term recovery outcomes. The company launched its first outpatient clinic in Mooresville, North Carolina and plans to open 10–15 sites over the next year. Eleanor Health is led by CEO and co-founder Corbin Petro and CMO and co-founder Nzinga Harrison, and its board includes health-policy leaders such as Andy Slavitt. Blue Cross and Blue Shield of North Carolina is collaborating with Eleanor Health to expand access to its services in North Carolina. Eleanor completed a major financing in July 2019 led by Mosaic Health Solutions (a Blue Cross NC subsidiary), with participation from Town Hall Ventures and Oxeon Ventures.

Total raised

$100M

Funding rounds

4

Latest round

Series D

Latest activity

Oct 2024